- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Applied Therapeutics Inc. Aktie
Verkaufen
Kaufen
Applied Therapeutics Inc. Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Applied Therapeutics Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-13,72 %
Intraday
-23,47 %
1 Woche
-90,86 %
1 Monat
-73,73 %
Seit Jahresbeginn
-71,79 %
1 Jahr
-91,06 %
3 Jahre
-96,40 %
5 Jahre
Wikifolio
Passender Service zu Applied Therapeutics Inc.
Webinar zu Applied Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,838-10,624
- Jahrestief / Hoch ($)0,838-10,624
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Applied Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Applied Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
